Literature DB >> 26758241

Lipidomics Biomarkers of Diet-Induced Hyperlipidemia and Its Treatment with Poria cocos.

Hua Miao1,2, Yu-Hui Zhao1, Nosratola D Vaziri2, Dan-Dan Tang1, Hua Chen1, Han Chen1, Mahyar Khazaeli2, Mehrdokht Tarbiat-Boldaji2, Leili Hatami2, Ying-Yong Zhao1,2.   

Abstract

Hyperlipidemia is a major cause of atherosclerotic cardiovascular disease. Poria cocos (PC) is a medicinal product widely used in Asia. This study was undertaken to define the alterations of lipid metabolites in rats fed a high-fat diet to induce hyperlipidemia and to explore efficacy and mechanism of action of PC in the treatment of diet-induced hyperlipidemia. Plasma samples were then analyzed using UPLC-HDMS. The untreated rats fed a high-fat diet exhibited significant elevation of plasma triglyceride and total and low-density lipoprotein (LDL) cholesterol concentrations. This was associated with marked changes in plasma concentrations of seven fatty acids (palmitic acid, hexadecenoic acid, hexanoylcarnitine, tetracosahexaenoic acid, cervonoyl ethanolamide, 3-hydroxytetradecanoic acid, and 5,6-DHET) and five sterols [cholesterol ester (18:2), cholesterol, hydroxytestosterone, 19-hydroxydeoxycorticosterone, and cholic acid]. These changes represented disorders of biosynthesis and metabolism of the primary bile acids, steroids, and fatty acids and mitochondrial fatty acid elongation pathways in diet-induced hyperlipidemia. Treatment with PC resulted in significant improvements of hyperlipidemia and the associated abnormalities of the lipid metabolites.

Entities:  

Keywords:  Poria cocos; fatty acid metabolism; hyperlipidemia; lipidomics; mass spectrometry; ultraperformance liquid chromatography

Mesh:

Substances:

Year:  2016        PMID: 26758241     DOI: 10.1021/acs.jafc.5b05350

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  20 in total

1.  Serum metabolites associate with lipid phenotypes among Bogalusa Heart Study participants.

Authors:  Xiaoying Gu; Changwei Li; Jiang He; Shengxu Li; Lydia A Bazzano; Jason M Kinchen; Wei Chen; Hua He; Dongfeng Gu; Tanika N Kelly
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-01-21       Impact factor: 4.222

Review 2.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

3.  Serum n-3 Tetracosapentaenoic Acid and Tetracosahexaenoic Acid Increase Following Higher Dietary α-Linolenic Acid but not Docosahexaenoic Acid.

Authors:  Adam H Metherel; Anthony F Domenichiello; Alex P Kitson; Yu-Hong Lin; Richard P Bazinet
Journal:  Lipids       Date:  2016-12-22       Impact factor: 1.880

4.  Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease.

Authors:  Ya-Long Feng; Gang Cao; Dan-Qian Chen; Nosratola D Vaziri; Lin Chen; Jun Zhang; Ming Wang; Yan Guo; Ying-Yong Zhao
Journal:  Cell Mol Life Sci       Date:  2019-05-30       Impact factor: 9.261

5.  Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis.

Authors:  Ming Wang; Dan-Qian Chen; Lin Chen; Gang Cao; Hui Zhao; Dan Liu; Nosratola D Vaziri; Yan Guo; Ying-Yong Zhao
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

Review 6.  Lipidomics in the Study of Hypertension in Metabolic Syndrome.

Authors:  Hemant Kulkarni; Manju Mamtani; John Blangero; Joanne E Curran
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

Review 7.  Utilizing Skyline to analyze lipidomics data containing liquid chromatography, ion mobility spectrometry and mass spectrometry dimensions.

Authors:  Kaylie I Kirkwood; Brian S Pratt; Nicholas Shulman; Kaipo Tamura; Michael J MacCoss; Brendan X MacLean; Erin S Baker
Journal:  Nat Protoc       Date:  2022-07-13       Impact factor: 17.021

8.  High-throughput liquid chromatography mass-spectrometry-driven lipidomics discover metabolic biomarkers and pathways as promising targets to reveal the therapeutic effects of the Shenqi pill.

Authors:  Wen-Xiu Li; Ai-Hua Zhang; Xiao-Hang Zhou; Yang Nan; Qi Liu; Hui Sun; Heng Fang; Xi-Jun Wang
Journal:  RSC Adv       Date:  2020-01-13       Impact factor: 4.036

9.  Disease-syndrome combination modeling: metabolomic strategy for the pathogenesis of chronic kidney disease.

Authors:  Shasha Li; Peng Xu; Ling Han; Wei Mao; Yiming Wang; Guoan Luo; Nizhi Yang
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

Review 10.  The Use of Omic Technologies Applied to Traditional Chinese Medicine Research.

Authors:  Dalinda Isabel Sánchez-Vidaña; Rahim Rajwani; Man-Sau Wong
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-31       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.